Abbott Healthcare Products B.v.

Elmar Wegener

Josephus H M Lange

Konrad Koehler

Michael Mlinaric

Pieter Smid

Sara Nuñez Garcia

This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R, R, (R), and (R)have the meanings given in the specification.

Growing community of inventors

Hannover, Germany

Elmar Wegener